ArticleGlobal advances in integrative medicine and health
Reported Distribution Patterns of Five Kampo Formulations in the United States: Observations from a Single Manufacturer and Comparison with Japanese Prescribing Trends.
Article in Global advances in integrative medicine and health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kampo medicine is a traditional Japanese herbal medical system that is integrated into contemporary healthcare in Japan but remains less widely characterized in the United States. Publicly available information regarding Kampo formulation utilization in the United States is limited. Methods: Manufacturer-reported distribution information was obtained through direct correspondence with Honso Pharmaceuticals, a company distributing Kampo formulations in the United States. The company provided a ranked list of its most commonly distributed Kampo formulations. The five highest-ranked formulations were reviewed descriptively and compared with published reports of Kampo prescribing patterns in Japan. Results: The five highest-ranked formulations reported by Honso Pharmaceuticals were Kamishoyosan, Shosaikoto, Hachimijiogan, Keishibukuryogan, and Juzentaihoto. These formulations differ from commonly prescribed Kampo formulations reported in Japanese health insurance and outpatient prescription datasets. Potential explanations may include differences in regulatory status, practitioner education, product availability, and healthcare-system structure between the United States and Japan. Conclusions: Manufacturer-reported distribution patterns suggest that Kampo formulation use in the United States may differ from prescribing trends reported in Japan. Because these observations are derived from a single manufacturer and lack patient-level utilization data, they should be interpreted cautiously. Additional research is needed to better characterize Kampo medicine utilization in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.